索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]吴勃萱,万仁辉.过氧化物酶体增殖物激活受体与糖尿病心肌病[J].国际心血管病杂志,2023,03:137-139，189.
点击复制

过氧化物酶体增殖物激活受体与糖尿病心肌病(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2023年03期
页码:
137-139，189
栏目:
综述
出版日期:
2023-05-30

文章信息/Info

Title:
-
作者:
吴勃萱; 万仁辉
200433 上海，海军军医大学基础医学院（吴勃萱）,200003 上海，海军军医大学附属长征医院内分泌科（万仁辉）
Author(s):
-
关键词:
糖尿病心肌病; 过氧化物酶体增殖物激活受体; 发病机制
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2023.03.003
文献标识码:
-
摘要:
过氧化物酶体增殖物激活受体（PPAR）是调节糖脂代谢的关键环节，PPAR在心功能障碍和糖尿病的发病机制中都起着重要作用，PPAR激动剂贝特类和噻唑烷二酮类作为降脂和降糖药已在临床使用多年。该文介绍PPAR及其相关药物在糖尿病心肌病发病机制中的研究进展。
Abstract:
-

参考文献/References

[1]Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications[J]. Nat Rev Endocrinol, 2018, 14(2):88-98.
[2]Rawshani A, Rawshani A, Franzén S, et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes[J]. N Engl J Med, 2018, 379(7):633-644.
[3]Gross B, Pawlak M, Lefebvre P, et al. PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD[J]. Nat Rev Endocrinol, 2017, 13(1):36-49.
[4]Lefere S, Puengel T, Hundertmark J, et al. Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages [J]. J Hepatol, 2020, 73(4):757-770.
[5]Li SZ, Yang BY, Du Y, et al. Targeting PPARα for the treatment and understanding of cardiovascular diseases[J]. Cell Physiol Biochem, 2018, 51(6):2760-2775.
[6]Tuomainen T,Tavi P.The role of cardiac energy metabolism in cardiac hypertrophy and failure[J]. Exp Cell Res, 2017, 360(1):12-18.
[7]Gentillon C, Li D, Duan MX, et al. Targeting HIF-1α in combination with PPARα activation and postnatal factors promotes the metabolic maturation of human induced pluripotent stem cell-derived cardiomyocytes[J]. J Mol Cell Cardiol, 2019, 132:120-135.
[8]Cluntun AA, Badolia R, Lettlova S, et al. The pyruvate-lactate axis modulates cardiac hypertrophy and heart failure[J]. Cell Metab, 2021, 33(3):629-648.e10.
[9]Montaigne D, Butruille L, Staels B. PPAR control of metabolism and cardiovascular functions[J]. Nat Rev Cardiol, 2021, 18(12):809-823.
[10] Chong CR, Clarke K, Levelt E. Metabolic remodeling in diabetic cardiomyopathy[J]. Cardiovasc Res, 2017, 113(4):422-430.
[11] Levelt E, Mahmod M, Piechnik SK, et al. Relationship between left ventricular structural and metabolic remodeling in type 2 diabetes[J]. Diabetes, 2016, 65(1):44-52.
[12] Jia GH, Hill MA, Sowers JR. Diabetic cardiomyopathy:an update of mechanisms contributing to this clinical entity[J]. Circ Res, 2018, 122(4):624-638.
[13] Wang L, Bi XT, Han JR. Silencing of peroxisome proliferator-activated receptor-alpha alleviates myocardial injury in diabetic cardiomyopathy by downregulating 3-hydroxy-3-methylglutaryl-coenzyme A synthase 2 expression[J]. IUBMB Life, 2020, 72(9):1997-2009.
[14] Nakamura M,Sadoshima J. Cardiomyopathy in obesity,insulin resistance and diabetes[J]. J Physiol, 2020, 598(14):2977-2993.
[15] Yin ZW, Zhao YR, He MY, et al. MiR-30c/PGC-1β protects against diabetic cardiomyopathy via PPARα[J]. Cardiovasc Diabetol, 2019, 18(1):7.
[16] Waldman M, Cohen K, Yadin D, et al. Regulation of diabetic cardiomyopathy by caloric restriction is mediated by intracellular signaling pathways involving ‘SIRT1 and PGC-1α’[J]. Cardiovasc Diabetol, 2018, 17(1):111.
[17] Campbell FM, Kozak R, Wagner A, et al. A role for peroxisome proliferator-activated receptor alpha (PPARalpha) in the control of cardiac malonyl-CoA levels:reduced fatty acid oxidation rates and increased glucose oxidation rates in the hearts of mice lacking PPARalpha are associated with higher concentrations of malonyl-CoA and reduced expression of malonyl-CoA decarboxylase[J]. J Biol Chem, 2002, 277(6):4098-4103.
[18] Haemmerle G, Moustafa T, Woelkart G, et al. ATGL-mediated fat catabolism regulates cardiac mitochondrial function via PPAR-α and PGC-1[J]. Nat Med, 2011, 17(9):1076-1085.
[19] Burkart EM, Sambandam N, Han XL, et al. Nuclear receptors PPARbeta/delta and PPARalpha direct distinct metabolic regulatory programs in the mouse heart[J]. J Clin Invest, 2007, 117(12):3930-3939.
[20] Liu J, Wang PY, Luo JW, et al. Peroxisome proliferator-activated receptor β/δ activation in adult hearts facilitates mitochondrial function and cardiac performance under pressure-overload condition[J]. Hypertension, 2011, 57(2):223-230.
[21] Marfella R, Di Filippo C, Portoghese M, et al. Myocardial lipid accumulation in patients with pressure-overloaded heart and metabolic syndrome[J]. J Lipid Res, 2009, 50(11):2314-2323.
[22] Jia GH, DeMarco VG, Sowers JR. Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy[J]. Nat Rev Endocrinol, 2016, 12(3):144-153.
[23] Son NH, Park TS, Yamashita H, et al. Cardiomyocyte expression of PPARgamma leads to cardiac dysfunction in mice[J]. J Clin Invest, 2007, 117(10):2791-2801.
[24] Legchenko E, Chouvarine P, Borchert P, et al. PPARγ agonist pioglitazone reverses pulmonary hypertension and prevents right heart failure via fatty acid oxidation[J]. Sci Transl Med, 2018, 10(438):eaao0303.
[25] Elam MB, Ginsberg HN, Lovato LC, et al. Association of fenofibrate therapy with long-term cardiovascular risk in statin-treated patients with type 2 diabetes[J]. JAMA Cardiol, 2017, 2(4):370-380.
[26] 中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)[J]. 中华糖尿病杂志, 2021, 13(4):315-409.
[27] Yamashita S, Masuda D, Matsuzawa Y. Pemafibrate,a new selective PPARα modulator:drug concept and its clinical applications for dyslipidemia and metabolic diseases[J]. Curr Atheroscler Rep, 2020, 22(1):5.
[28] Matsuba I, Matsuba R, Ishibashi S, et al. Effects of a novel selective peroxisome proliferator-activated receptor-α modulator, pemafibrate,on hepatic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance[J]. J Diabetes Investig, 2018, 9(6):1323-1332.
[29] Das Pradhan A, Glynn RJ, Fruchart JC, et al. Triglyceride lowering with pemafibrate to reduce cardiovascular risk [J]. N Engl J Med, 2022, 387(21):1923-1934.
[30] Dludla PV, Nyambuya TM, Johnson R, et al. Metformin and heart failure–related outcomes in patients with or without diabetes:a systematic review of randomized controlled trials[J]. Heart Fail Rev, 2021, 26(6):1437-1445.
[31] Wu LJ, Wang K, Wang W, et al. Glucagon-like peptide-1 ameliorates cardiac lipotoxicity in diabetic cardiomyopathy via the PPARα pathway[J]. Aging Cell, 2018, 17(4):e12763.
[32] Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med, 2017, 377(13):1228-1239.[33] Nesti L, Tricò D, Mengozzi A, et al. Rethinking pioglitazone as a cardioprotective agent:a new perspective on an overlooked drug[J]. Cardiovasc Diabetol, 2021, 20(1):109.

备注/Memo

备注/Memo:
通信作者：万仁辉， E-mail：wanrh_nmu@126.com
更新日期/Last Update: 2023-05-30